Current Management of Intracerebral Haemorrhage in China
Author Information
Author(s): Wei Jade W, Huang Yining, Wang Ji-Guang, Liu Ming, Wong Lawrence KS, Huang Qifang, Wu Li'e, Heeley Emma L, Arima Hisatomi, Anderson Craig S, ChinaQUEST Investigators
Primary Institution: The George Institute for Global Health
Hypothesis
What are the current practices for managing and preventing intracerebral haemorrhage in China?
Conclusion
The management of ICH in China is characterized by high rates of use of intravenous haemodiluting agents, neuroprotectants, and traditional Chinese medicine, along with antihypertensives for secondary prevention.
Supporting Evidence
- 96% of ICH patients received intravenous haemodiluting agents.
- 72% of patients were treated with neuroprotectants.
- 9% of patients underwent neurosurgery.
- 13% in-hospital mortality rate was reported.
- 78% of patients with hypertension continued antihypertensive therapy at 3 months post-stroke.
Takeaway
Doctors in China use a lot of different treatments for a type of stroke called intracerebral haemorrhage, but many of these treatments aren't proven to work well.
Methodology
Data were collected from a multi-centre, prospective hospital registry study involving 62 hospitals in China during 2006-07.
Potential Biases
Potential survivor bias and recall bias in self-reported medical history.
Limitations
The study may not represent management practices in smaller or rural hospitals, and specific clinical details about the haematoma were not recorded.
Participant Demographics
Patients were predominantly middle-aged, with a history of hypertension, and included both genders.
Statistical Information
P-Value
0.001
Confidence Interval
1.55, 4.35
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website